Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

[1]  G. Biondi-Zoccai,et al.  Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events , 2012, BioDrugs.

[2]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[3]  N. Frangogiannis,et al.  Regulation of the inflammatory response in cardiac repair. , 2012, Circulation research.

[4]  N. Voelkel,et al.  The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse , 2011, Proceedings of the National Academy of Sciences.

[5]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[6]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[7]  B. V. Van Tassell,et al.  Interleukin‐1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse , 2010, European journal of heart failure.

[8]  Anindita Das,et al.  Interleukin-1 Trap Attenuates Cardiac Remodeling After Experimental Acute Myocardial Infarction in Mice , 2010, Journal of cardiovascular pharmacology.

[9]  J. McMurray,et al.  Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? , 2009, American heart journal.

[10]  K. Dickstein,et al.  C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. , 2009, European heart journal.

[11]  G. Biondi-Zoccai,et al.  Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction , 2008, Circulation.

[12]  Antti Saraste,et al.  Contrast-enhanced magnetic resonance imaging in the assessment of myocardial infarction and viability , 2008, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[13]  J. Burchenal,et al.  Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. , 2005, European heart journal.

[14]  D. Furst.  Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. , 2004, Clinical therapeutics.

[15]  R. Doughty,et al.  Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction: The CAPRICORN Echo Substudy , 2004, Circulation.

[16]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[17]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[18]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[19]  A. Gavazzi,et al.  [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[20]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[21]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[22]  A. Rebuzzi,et al.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.